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Myocardial infarction (MI) is one of the deadliest forms of ischemic heart disease,
resulting in millions of annual deaths globally. MI is characterized by cardiomyocyte
cell death leading to compromised heart function due to insufficient supply of
1oxygenated blood to the heart. In the clinical setting, percutaneous coronary
intervention (PCI) is the gold standard to return blood flow as soon as possible.
However, studies have shown that the restoration of blood to ischemic tissue
(reperfusion) causes a paradoxical exacerbation of cardiomyocyte dysfunction and
death in a phenomenon known as ischemia-reperfusion (I/R) injury (Fig.1) that
threatens the long-term viability of the heart.1 There are currently no therapeutic
interventions that have been shown to clinically improve cardiac function and reduce
infarct size in patients who have suffered from I/R-induced MI injury.
In previous small and large animal studies of myocardial I/R injury (ex vivo and in
vivo), activation of opioid receptors is known to mediate cardioprotective effects
during preconditioning (prior to ischemia) that result in the resolution of cardiac
arrhythmia or the reduction of infarct size.2,3,4,5 The heart predominantly expresses
delta (δ) and kappa (κ) opioid receptors throughout the atria and ventricles, making
these opioid receptors attractive therapeutic targets.4,5
In our previous studies, a novel three-amino acid peptide (tripeptide), that is
structurally similar to other amino acid-based delta and kappa-opioid receptor
agonists, demonstrated a significant reduction in infarct size and improved cardiac
function when administered during preconditioning in isolated rat hearts using the
Langendorf model (ex vivo).6
To identify the specific opioid receptor subtype responsible, the cardioprotective
effects of tripeptide combined with either Naloxone (NX; broad-spectrum opioid
antagonist), Nor-binaltorphine (BNI; selective kappa-opioid receptor antagonist), or
with Naltrindole (NTI; selective delta-opioid receptor antagonist) were studied. Co-
treatment with either NX or BNI were found to inhibit the cardioprotective effects of
tripeptide, indicating that tripeptide was a kappa-opioid agonist. Surprisingly, the co-
treatment of tripeptide with NTI augmented the cardioprotective effects of
tripeptide alone. The goal of this study was to determine the relative contribution of
tripeptide and NTI in mediating the observed reduction of infarct size and restoration
of cardiac function (e.g., left ventricular developed pressure [LVDP], the maximal rate
of rise of LVDP [+dP/dtmax ], and the maximal rate of decline of LVDP [-dP/dt min]). To
this end, the study evaluated the effects of the opioid antagonists: NTI, BNI, and NX
independently in a Langendorf rat heart model.
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INTRODUCTION
Hearts from male Sprague-Dawley rats (275-325g,  
Charles River, Springfield MA) were isolated and
subjected to 30 min global ischemia and 45 min
reperfusion using a modified Langendorf heart
preparation (Figure 2).
Naltrindole (NTI; 5 µM), Naloxone (NX; 10 µM), and Nor-
binaltorphine (BNI; 5 µM) were given prior (last 5 min of
baseline [15 min]) to the ischemic period (pre- treatment
[i.e. preconditioning]) and during the initial 5 min of
reperfusion (post-treatment).2,6Control I/R hearts did not
receive any treatment.
Left ventricular (LV) cardiac function indices were
measured using a pressure transducer (Fig.3). At the end
of reperfusion (45min), hearts were frozen, cut into 2
mm sections, and stained with 1% triphenyl tetrazolium
chloride (TTC). Weight of infarcted heart tissue (pale) was
compared to total tissue at risk.
Statistical Analysis: All data in the figures are presented
as means ± S.E.M. ANOVA analysis using Student-
Neuman-Keuls test. Probability values of p<0.05 were
considered statistically significant.
RESULTS
Figure 4. Time course of +dP/dt max for  
Control I/R, NX (10μM) + I/R,   NTI (5μM)
+ I/R, and BNI (5μM) + I/R treated hearts.  
NTI + I/R significantly improved +dP/dt  
max during 20 min to 45 min of  
reperfusion. † p<0.05, NTI vs. all groups.
Figure 5. Time course of -dP/dt min for  
Control I/R, NX (10μM) + I/R, NTI  
(5μM) + I/R, and BNI (5μM) + I/R treated  
hearts. NTI + I/R significantly improved -
dP/dt min during 30 min to 45 min of  
reperfusion. *p<0.05, NTI vs. Control.
RESULTS (Cont.)
Table 1. Cardiac function baseline, reperfusion 15 mins, and final values (reperfusion 45 min) for control I/R; NX  
(10 μM) + I/R; NTI (5 μM) + I/R; and BNI (5 μM) + I/R treated hearts. NTI + I/R significantly improved post-
reperfused cardiac function compared to control I/R (*p<0.05; **p<0.01). NTI exerted a negative ionotropic effect  
on cardiac function during preconditioning (#p<0.05; ##p<0.01, baseline NTI vs preconditioning NTI) which was  
associated with significant attenuation of ischemic peak pressure change compared to controls. Abbreviations:  
LVDP, left ventricular developed pressure (LVESP-LVEDP); +dP/dt max, maximal rate of rise in LVDP; -dP/dt min,  
maximal rate of decline in LVDP; LVESP, left ventricular end systolic pressure; LVEDP, left ventricular end diastolic  
pressure. Naloxone (NX), naltrindole (NTI), nor-binaltorphine (BNI) and ischemia-reperfusion (I/R).
CONCLUSION
Results suggest that:
• Pretreatment with the delta-opioid receptor antagonist NTI leads to dramatic
restoration of post-reperfused heart function (LVEDP, -dP/dTmin, and +dP/dTmax) to near
pre-ischemic baseline levels.
• NTI may elicit direct cardioprotective effects on the heart during I/R injury that is
independent of opioid receptor inhibition.
• There is a direct correlation between the attenuation of final LVEDP and infarct size
which suggests that NTI mitigates myocardial I/R injury by preventing cardiac
hypercontracture.
In future studies, we will:
• Determine whether the observed cardioprotective effects of NTI alone are
reproducible in an in vivo rat myocardial I/R model.
• Examine potential mechanisms of NTI pretreatment that are responsible for the
significant increase in resistance to I/R damage, and whether these effects are
exerted independently of the delta opioid receptor.
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Table 2. Representative TTC stained mid-wall sections from isolated perfused rat hearts. Weight ratios of  
infarcted heart tissue vs at-risk (to heart tissue) left ventricular heart tissue in I/R as determined by TTC staining.  
Healthy red heart tissue and infarcted tissue stained white. NTI + I/R significantly decreased infarct size compared  
to control I/R. (†† p<0.01, NTI vs. all groups). Abbreviations: Triphenyl tetrazolium chloride (TTC), naltrindole (NTI)  
and ischemia-reperfusion (I/R), naloxone (NX) and nor-binaltorphine (BNI).
Figure 1. Proposed Mechanism of Ischemia/Reperfusion Injury in Cardiomyocytes. Acute myocardial
ischemia results in a decrease in pH due to the build-up of lactic acid from anaerobic conditions. This
results in closed mitochondrial permeability transition pore (MPTP). Reperfusion results in washout of
lactic acid, resulting in the rapid restoration of physiological pH, which stops the inhibitory effect on the
MPTP pore, induces Ca2+ overload, and cardiomyocyte hyper-contracture. The restoration of the
mitochondrial membrane potential drives Ca2+ into the mitochondria, which can also induce MPTP
opening (i.e. mitochondrial dysfunction) and cardiac contractile dysfunction. Neutrophils accumulate in
the infarcted myocardial tissue in response to the release of chemo-attractants and generate reactive
oxygen species (ROS) (adapted).1 Naltrindole (NTI) exerted direct negative ionotropic effects on the heart
during preconditioning (Figure 6) that correlated with attenuation of cardiac hypercontracture during
reperfusion as evidenced by the dramatic restoration of left ventricular end diastolic pressure at 15 and
45min reperfusion (see Table 1).
METHODOLOGY
Figure 2. Flow diagram of the
experimental protocol (left) and
representative picture of isolated

















Figure 3. Representative tracings of  
the maximal rate of rise of left  
ventricular developed pressure  
(LVDP) [+dP/dtmax] and maximal rate  
of decline of LVDP [-dP/dtmin] for  
control I/R (left) and I/R + NTI (right)  
treated hearts at 45 min reperfusion  
following 30 min global ischemia.
Figure 6. LVEDP ischemic peak pressure  
(IPP) change for Control, NX, NTI, and BNI.  
IPP change represents the peak pressure  
difference between preconditioning and  
IPP. NTI + I/R significantly attenuated the  
rise in IPP during ischemia. **p<0.01, NTI  
vs Control.
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  Baseline 2379±65 -1660±87 105±4 8±1 97±3 265±7 20±2
  Preconditioning (PC) 2455±72 -1736±90 105±3 9±1 97±3 266±8 19±2
  Ischemia Peak Pressure (IPP) 11±5 -13±7 39±4 38±4 0.39±0.04 699±121 0
  IPP Change --- --- --- 29±6 --- --- ---
  Reperfusion 15 min 532±181 -437±137 98±5 72±6 27±9 225±24 9±0.8
  Reperfusion 45 min 800±168 -687±139 101±6 61±5 41±9 281±26 9±1
NTI (n=7)
  Baseline 2312±106 -1622±102 97±2 6±1 92±2 297±8 19±1
  Preconditioning (PC) 1581±379**## -991±305## 76±12** 17±5## 60±10**## 278±10 19±1
  Ischemia Peak Pressure (IPP) 215±185 -221±192 21±3 18±3 2.5±1.6 287±133* 0
  IPP Change --- --- --- 1±7 --- --- ---
  Reperfusion 15 min 729±151 -655±114 78±10* 39±7** 39±9 219±14 12±1
  Reperfusion 45 min 1830±90** -1185±82** 100±6 18±4** 82±4** 261±5 11±1
NX (n=6)
  Baseline 2496±69 -1696±96 100±3 8±1 92±3 256±5 16±2
  Preconditioning (PC) 2433±102 -1624±134* 97±6 8±1 89±6 244±7 15±2
  Ischemia Peak Pressure (IPP) 146±70 -140±68 26±6 26±6 0.85±0.24 676±137 0
  IPP Change --- --- --- 18±6 --- --- ---
  Reperfusion 15 min 628±206 -551±166 91±9 67±9 24±5 208±34 6±1
  Reperfusion 45 min 878±113 -692±112 101±10 65±8 36±7 240±25 6±1
BNI (n=7)
  Baseline 2371±80 -1642±51 94±3 6±1 88±2 288±11 20±2
  Preconditioning (PC) 2319±83 -1566±85 92±5 6±1 86±4 279±10 19±2
  Ischemia Peak Pressure (IPP) 24±19 -22±17 34±8 33±8 0.87±0.34 415±168 0
  IPP Change --- --- --- 27±8 --- --- ---
  Reperfusion 15 min 483±96 -461±96 89±3 70±3 18±5 301±43 9±1
  Reperfusion 45 min 729±93 -682±110 94±3 62±2 32±4 250±17 8±1
